다발성 골수종

96개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved96 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleZhejiang UniversityPhase 1

CD19/BCMA-targeted CAR-T cells (CD19/BCMA-targeted CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR-T (CD19/CD20/BCMA CAR-T)

Relapsed; Refractory · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

BZE2204 (CD19/CD22/BCMA CAR-T cells, CD19/CD22/BCMA CAR-T cells(BZE2204))

Idiopathic Inflammatory Myopathies(IIM); Immune Thrombocytopenia(ITP) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (CT-P44, CT-P44(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleO&D BioTech Group CO., LimitedPhase 1

Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D (Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D)

Relapsed or Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
CGTLimited DatastaleCartesian TherapeuticsPhase 1

Descartes-15 (Descartes-15)

Refractory Multiple Myeloma; Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

daratumumab (Darzalex, Early treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Janssen
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

3 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (3 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

up to 9 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (up to 9 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLiping DouPhase 1

In vivo BCMA/GPRC5D Tandem Dual CAR-T cell (In vivo BCMA/GPRC5D Tandem Dual CAR-T cell)

Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleSanofiPhase 2

Isatuximab SC-OBDS (Isatuximab SC-OBDS)

Plasma Cell Myeloma Refractory · FRα

#FR#Antibody#Phase2#monoclonal-antibody#PlasmaCellMyelomaRefractory+1
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed BCMA CAR-T cells. (Metabolically Armed BCMA CAR-T cells.)

Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

4 / 5 pages

← PreviousNext →